RIA
CRSP icon

Realta Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Realta Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-614
Closed -$44K – 514
2019
Q4 		$44K Sell
614
-25
-4% -$1.36K 0.01% 696
2019
Q3 		$26K Buy
+639
New +$30.5K 0.01% 839
2019
Q2 		– Sell
-1,035
Closed -$38K – 1721
2019
Q1 		$38K Buy
+1,035
New +$35.8K 0.02% 614

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Realta Investment Advisors's CRSP Position: Q1 2020 in Review

Realta Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 614 shares — an estimated $44K sold.

Realta Investment Advisors first reported a position in CRSP in Q1 2019 and held it in 3 quarters. The position peaked at $44K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Realta Investment Advisors reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 614 CRISPR Therapeutics shares in Q1 2020, an estimated $44K.
  • Realta Investment Advisors first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 3 quarters.
  • Realta Investment Advisors's CRISPR Therapeutics position peaked at $44K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.